

To,
BSE Limited
P. J. Towers,
Dalal Street,
Mumbai – 400001

Date: 10.11.2023

Unit: Decipher Labs Limited (Scrip Code-524752)

Sub: Outcome of Board Meeting for the quarter 30.09.2023 under regulation 30 and 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations, 2015.

Dear Sir/ Madam,

With reference to the subject cited, this is to inform the Exchange that the Board of Directors of **Decipher Labs Limited** at its meeting held on Friday, the 10th day of November, 2023 at 5.30 P.M. at registered office of the Company for the quarter ended 30.09.2023 considered and approved the following:

1. Un- Audited Financial Results (standalone and consolidated) for the quarter and half year ended 30.09.2023. **(Attached)**
2. Limited Review Report (standalone and consolidated) for the Quarter and half year ended 30.09.2023. **(Attached)**

The meeting concluded at 08:50 P.M.

This is for the information and records of the Exchanges, please.

Thanking you.

Yours Faithfully
For Decipher Labs Limited

Siva Kumar Reddy Chappidi
Company Secretary and Compliance Officer

Encl. as above

DECIPHER LABS LIMITED

Standalone Statement of Assets and Liabilities as on 30 September 2023

All amounts in ₹ Lakhs, unless otherwise stated

| Particulars | Note | As at 30 Sep 2023 | As at 31 March 2023 |
|-------------------------------------------------------------------------------|------|----------------------|------------------------|
| I. ASSETS | | | |
| Non-current assets | | | |
| (a) Property, Plant and Equipment | 3 | 11.14 | 11.87 |
| (b) Financial assets | | | |
| Investments | 4 | 866.41 | 866.41 |
| (c) Other non-current assets | 5 | 0.30 | 0.30 |
| (d) Deferred Tax Assets | | 1.86 | 2.00 |
| Current Assets | | | |
| (a) Inventories | 6 | - | - |
| (b) Financial assets | | | |
| (i) Trade receivables | 7.1 | - | 12.74 |
| (ii) Cash and cash equivalents | 7.2 | 0.89 | 5.62 |
| (iii) Other financial assets | 7.3 | - | - |
| (c) Current tax assets | 8 | 0.03 | 0.03 |
| (d) Other current assets | 9 | 5.11 | - |
| TOTAL ASSETS | | 885.75 | 898.98 |
| II. EQUITY AND LIABILITIES | | | |
| Equity | | | |
| (a) Equity share capital | 10 | 1,010.00 | 1,010.00 |
| (b) Other equity | 11 | (139.2768) | (119.57) |
| Non-current assets | | | |
| (a) Deferred tax liabilities (net) | 12 | - | - |
| Current Liabilities | | | |
| (a) Financial liabilities | | | |
| (i) Borrowings | 13.1 | - | - |
| (ii) Trade Payables | 13.2 | | |
| a) Total outstanding dues of Micro and small enterprises | | - | - |
| b) Total outstanding dues of creditors other than Micro and small enterprises | | - | - |
| (iii) Other financial liabilities | 13.3 | 14.839 | 7.73 |
| (b) Other current liabilities | 14 | 0.185 | 0.81 |
| TOTAL EQUITY AND LIABILITIES | | 885.75 | 898.98 |

For and on behalf of the Board



Sushant Mohan Lal
Director
DIN: 01227151



Place: Hyderabad
Date: 10.11.2023

DECIPHER LABS LIMITED
(CIN CL23230TG1985PLC006781)

Regd. off: 4th Floor, Plot No.94, Sagar Society
Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034
URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-48536100

Statement of Standalone Financial Results For the Quarter and six months Ended 30th September, 2023

All amounts in ₹ Lakhs, unless otherwise stated

| Particulars | Quarter ended | | | Half Year Ended | | Year ended |
|-------------------------------------------------|---------------|------------|------------|-----------------|------------|------------|
| | 30.09.2023 | 30.06.2023 | 30.09.2022 | 30.09.2023 | 30.09.2022 | 31.03.2023 |
| | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| I. Revenue from operations | - | - | 12.23 | - | 65.13 | 81.00 |
| II. Other income | 0.50 | 0.50 | 1.26 | 1.00 | 1.84 | 2.82 |
| III. Total Income (I + II) | 0.50 | 0.50 | 13.49 | 1.00 | 66.97 | 83.82 |
| IV. Expenses | | | | | | |
| Purchase of Stock in trade | - | - | 3.15 | - | 34.65 | 47.25 |
| Changes in inventories of stock in trade | - | - | - | - | - | 4.42 |
| Employee Benefits Expense | 4.25 | 4.25 | 4.24 | 8.50 | 8.29 | 20.11 |
| Finance Costs | - | - | - | - | - | - |
| Depreciation expense | 0.37 | 0.36 | 1.45 | 0.73 | 2.92 | 5.74 |
| Other expenses | 4.89 | 6.44 | 6.32 | 11.33 | 18.33 | 46.03 |
| Total expenses | 9.51 | 11.05 | 15.17 | 20.56 | 64.19 | 123.55 |
| V. Profit before Exceptional Items (III - IV) | (9.02) | (10.55) | (1.67) | (19.57) | 2.77 | (39.74) |
| VI. Exceptional Items | - | - | - | - | - | 224.15 |
| VII. Profit after Exceptional items (V - VI) | (9.02) | (10.55) | (1.67) | (19.57) | 2.77 | (263.89) |
| VIII. Tax expense: | | | | | | |
| (1) Current tax | - | - | - | - | - | - |
| (2) Deferred tax | (1.54) | 1.67 | 0.38 | 0.13 | 0.51 | 2.14 |
| IX. Profit/(Loss) for the period (VII-VIII) | (7.48) | (12.22) | (2.05) | (19.70) | 2.26 | (261.75) |
| X. Other comprehensive Income | - | - | - | - | - | - |
| XI. Total comprehensive income for the year | (7.48) | (12.22) | (2.05) | (19.70) | 2.26 | (261.75) |
| Paid Up Equity Share Capital (FV of Rs 10 each) | 1,010.00 | 1,010.00 | 1,010.00 | 1,010.00 | 1,010.00 | 1,010.00 |
| XII. Earning per equity share | | | | | | |
| (1) Basic | (0.07) | (0.12) | (0.02) | (0.20) | 0.02 | (2.59) |
| (2) Diluted | (0.07) | (0.12) | (0.02) | (0.20) | 0.02 | (2.59) |

Notes

1. The operations of the Group relate to two segments viz, Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

| Particulars | Quarter ended | | | Half Year Ended | | Year Ended |
|-------------------------------------------------------------------|---------------|------------|------------|-----------------|------------|------------|
| | 30.09.2023 | 30.06.2023 | 30.09.2022 | 30.09.2023 | 30.09.2022 | 31.03.2023 |
| | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| Segment Revenue | | | | | | |
| a) Manufacturing and Trading of Pharmaceutical drugs | - | - | 4.10 | 52.02 | 49.10 | 64.96 |
| b) Consultancy Services | - | - | 8.14 | 16.04 | 16.04 | 16.04 |
| Total Sales | - | - | 12.23 | 68.06 | 65.14 | 81.00 |
| Less: Inter Segment Revenue | - | - | - | - | - | - |
| Total Revenue from Operations | - | - | 12.23 | 68.06 | 65.14 | 81.00 |
| Segment Result (Profit Before Tax and Interest from each Segment) | | | | | | |
| a) Manufacturing and Trading of Pharmaceutical drugs | (9.02) | (10.55) | (0.56) | (4.46) | 2.09 | 28.70 |
| b) Consultancy Services | - | - | (1.11) | (1.38) | 0.68 | 7.09 |
| Total | (9.02) | (10.55) | (1.67) | (5.84) | 2.77 | 35.80 |
| Less: Interest | - | - | - | - | - | - |
| Total Profit before tax | (9.02) | (10.55) | (1.67) | (5.84) | 2.77 | 35.80 |
| Capital employed (Segment assets - segment liabilities) | | | | | | |
| Segment assets | | | | | | |
| a) Manufacturing and trading of Pharmaceutical drugs | 885.75 | 886.72 | 1,149.84 | 919.19 | 1,149.84 | 884.94 |
| b) Consultancy Services | - | - | 20.82 | 12.83 | 20.82 | 14.04 |
| Total Assets | 885.75 | 886.72 | 1,170.65 | 932.02 | 1,170.66 | 898.98 |
| Segment liabilities | | | | | | |
| a) Manufacturing and trading of Pharmaceutical drugs | 15.02 | 8.50 | 15.28 | 8.97 | 11.52 | 8.55 |
| b) Consultancy Services | - | - | - | - | - | - |
| c) Unallocated liabilities | - | - | 0.94 | 0.37 | - | - |
| Total Liabilities | 15.02 | 8.50 | 16.22 | 9.35 | 11.52 | 8.55 |

2. The above results for the quarter ended 30th September 2023 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 10.11.2023.

3. The financial results of the Company have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act') read

with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

4. Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.

For and on behalf of the Board



Sushant Mohan Lal
Director
DIN: 01227151



Place: Hyderabad
Date: 10.11.2023

DECIPHER LABS LIMITED
STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31ST MARCH, 2023

All amounts in ₹ Lakhs, unless otherwise stated

| Particulars | Year ended 31st March, 2023 | | Year ended 31st March, 2023 | |
|---------------------------------------------------------------|--------------------------------|----------------|--------------------------------|----------------|
| | | | | |
| A. CASH FLOW FROM OPERATING ACTIVITIES | | | | |
| Profit before tax | | (19.57) | | (263.89) |
| Adjustments for : | | | | |
| Depreciation expense | | 0.73 | | 5.74 |
| Loss on sale of asset | | - | | 7.34 |
| Advance to suppliers written off | | - | | - |
| Balances written off | | - | | 224.15 |
| Operating Profit before Working Capital Changes | | (18.84) | | (26.66) |
| Adjustments for: | | | | |
| (Increase) / Decrease in Trade Receivables | 12.74 | | 8.80 | |
| (Increase) / Decrease in Inventories | - | | 4.42 | |
| (Increase) / Decrease in Other Assets | (5.11) | | 5.28 | |
| Increase / (Decrease) in Trade Payable | - | | - | |
| Increase / (Decrease) in Other Liabilities | 6.48 | | 0.51 | |
| | | 14.11 | | 19.01 |
| Cash Generated from Operations | | (4.73) | | (7.65) |
| Direct Taxes Paid | | - | | - |
| Net Cash generated from/(used in) Operating Activities | | (4.73) | | (7.65) |
| B. CASH FLOW FROM INVESTING ACTIVITIES | | | | |
| Purchase/Sale of Property, Plant & Equipment | - | | 8.50 | |
| Investments | - | | - | |
| Net Cash used in Investing Activities | | - | | 8.50 |
| C. CASH FLOW FROM FINANCING ACTIVITIES | | | | |
| Repayment of Short Term Borrowings (net) | - | | - | |
| Net Cash generated from Financing Activities | | - | | - |
| Net decrease in Cash and Cash Equivalents | | (4.72) | | 0.85 |
| Cash and Cash Equivalents at the beginning of the year | | 5.61 | | 4.76 |
| Cash and Cash Equivalents at the end of the year | | 0.89 | | 5.61 |

For and on behalf of the Board



Sushant Mohan Lal
Director
DIN: 01227151



Place: Hyderabad
Date: 10.11.2023

Decipher Labs Limited
(CIN CL23230TG1986PLC006781)
Regd.off: 4th Floor, Plot No.94, Sagar Society,
Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034
URL: www.combatdrugs.in, email: info@combatdrugs.in, Ph: 040-48536100
Consolidated Statement of Asset and Liabilities as on 30th September, 2023

All amounts in ₹ Lakhs, unless otherwise stated

| Particulars | As at 30 Sep 2023 (Unaudited) | As at 30 March 2023 (Audited) |
|-------------------------------------------------------------------------------------------|----------------------------------|----------------------------------|
| I. ASSETS | | |
| Non-current Assets | | |
| (a) Property, Plant and Equipment | 92.75 | 96.63 |
| (b) Investment | 338.35 | 375.68 |
| (c) Deferred tax asset (net) | 51.22 | 100.69 |
| (d) Goodwill | 220.00 | 234.82 |
| (e) Financial assets | | |
| Other financial asset | - | - |
| (f) Other non current assets | 0.30 | 0.30 |
| Current Assets | | |
| (a) Inventories | - | - |
| (b) Financial assets | | |
| (i) Trade receivables | 593.22 | 985.43 |
| (ii) Cash and cash equivalents | 818.78 | 741.77 |
| (iii) Other Financial Asset | 44.88 | 148.99 |
| (c) Other current assets | 233.69 | 132.15 |
| TOTAL ASSETS | 2,393.20 | 2,816.46 |
| II. EQUITY AND LIABILITIES | | |
| Equity | | |
| (a) Equity share capital | 1,010.00 | 1,010.00 |
| (b) Other equity | 1,050.07 | 1,310.86 |
| Liabilities | | |
| Non-Current Liabilities | | |
| (a) Financial liabilities | | |
| (i) Borrowings | - | - |
| (b) Deferred tax Liabilities (Net) | - | - |
| Current Liabilities | | |
| (a) Financial liabilities | | |
| (i) Borrowings | - | 94.94 |
| (ii) Lease Liability | - | - |
| (ii) Trade payables | | |
| a) Total outstanding dues of Micro enterprises and small enterprises | - | - |
| b) Total outstanding dues of creditors other than Micro enterprises and small enterprises | 98.06 | 120.14 |
| (iii) Other Financial liabilities | 234.88 | 279.71 |
| (b) Other current liabilities | 0.19 | 0.81 |
| (c) Current Tax Liabilities (net) | - | - |
| TOTAL EQUITY AND LIABILITIES | 2,393.20 | 2,816.46 |

For and on behalf of the Board



Sushant Mohan Lal
Director
DIN: 01227151



Place: Hyderabad
Date: 10.11.2023

Decipher Labs Limited
(CIN CL23230TG1986PLC005781)
Regd. off: 4th Floor, Plot No.94, Sagar Society,
Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034
URL: www.decipherlabs.in, email: info@decipherlabs.in, Ph: 040-48536100
Consolidated Unaudited Financial Results For the Quarter and Hal Year Ended 30 September 2023

All amounts in ₹ Lakhs, unless otherwise stated

| Particulars | Quarter Ended | | | Half Year Ended | | Year Ended |
|--------------------------------------------------------------------------------------|---------------|------------|------------|-----------------|------------|------------|
| | 30.09.2023 | 30.06.2023 | 30.09.2022 | 30.09.2023 | 30.09.2022 | 31.03.2023 |
| | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| I. Revenue from operations | 749.24 | 950.87 | 1,212.24 | 1,700.11 | 2,474.16 | 4,557.27 |
| II. Other income | 13.79 | 0.50 | 266.03 | 14.29 | 952.38 | 737.06 |
| III. Total revenue (I + II) | 763.03 | 951.37 | 1,478.27 | 1,714.40 | 3,426.54 | 5,294.33 |
| IV. Expenses | | | | | | |
| Purchase of Stock-in-Trade | - | - | 3.15 | - | 34.65 | 47.25 |
| Changes in inventories of finished goods and stock in trade | - | - | - | - | - | 4.42 |
| Employee benefits expense | 777.92 | 804.83 | 1,178.20 | 1,582.75 | 2,241.38 | 4,119.12 |
| Finance costs | 0.00 | 0.52 | 11.58 | 0.52 | 22.94 | 42.69 |
| Depreciation and amortisation expense | 11.28 | 11.15 | 10.48 | 22.43 | 20.24 | 42.75 |
| Other expenses | 187.71 | 159.79 | 117.65 | 347.50 | 359.13 | 1,229.88 |
| Total expenses | 976.91 | 976.29 | 1,321.06 | 1,953.20 | 2,678.34 | 5,486.11 |
| V. Profit/(Loss) before Exceptional item (III - IV) | (213.88) | (24.92) | 157.21 | (238.80) | 748.20 | (191.78) |
| VI. Exceptional items | - | - | - | - | - | 224.15 |
| VII. Profit/(Loss) after Exceptional item (III - IV) | (213.88) | (24.92) | 157.21 | (238.80) | 748.20 | (415.93) |
| VIII. Tax expense: | | | | | | |
| (1) Current tax | - | - | 37.52 | - | 37.52 | (46.89) |
| (2) Deferred tax | (19.80) | 69.89 | 0.38 | 50.29 | 0.51 | (100.81) |
| IX. Profit/(Loss) for the period (V-VI) | (194.28) | (94.81) | 119.31 | (289.09) | 710.17 | (268.23) |
| X. Other comprehensive income | | | | | | |
| Items that will be reclassified to statement of profit and loss | - | - | - | - | - | - |
| Exchange differences on translating the financial statements of foreign Subsidiaries | 11.92 | 2.23 | 101.24 | 14.15 | 159.20 | 172.57 |
| XI. Total comprehensive income for the year | (182.36) | (92.58) | 220.55 | (274.94) | 869.37 | (95.66) |
| Paid Up Equity Share Capital (FV of Rs 10 each) | 1,010.00 | 1,010.00 | 1,010.00 | 1,010.00 | 1,010.00 | 1,010.00 |
| XI. Earning per equity share | | | | | | |
| (1) Basic | (1.92) | (0.94) | 1.18 | (2.86) | 7.03 | (2.66) |
| (2) Diluted | (1.92) | (0.94) | 1.18 | (2.86) | 7.03 | (2.66) |

Notes:

1. The operations of the Group relate to two segments viz; Manufacturing and Trading of Pharmaceutical drugs and Consultancy Services.

Segment Information:

| Particulars | Quarter Ended | | | Half Year Ended | | Year Ended |
|--------------------------------------------------------------------------|---------------|------------|------------|-----------------|------------|------------|
| | 30.09.2023 | 30.06.2023 | 30.09.2022 | 30.09.2023 | 30.09.2022 | 31.03.2023 |
| | Unaudited | Unaudited | Unaudited | Unaudited | Unaudited | Audited |
| Segment Revenue | | | | | | |
| a) Manufacturing and Trading of Pharmaceutical drugs | - | - | 45.00 | - | 49.10 | 68.82 |
| b) Consultancy Services | 749.24 | 950.87 | 1,216.92 | 1,700.11 | 2,425.07 | 4,488.45 |
| Total Sales | 749.24 | 950.87 | 1,261.92 | 1,700.11 | 2,474.17 | 4,557.27 |
| Less: Inter Segment Revenue | - | - | - | - | - | - |
| Total Revenue from Operations | 749.24 | 950.87 | 1,261.92 | 1,700.11 | 2,474.17 | 4,557.27 |
| Segment Result (Profit Before Tax and Interest from each Segment) | | | | | | |
| a) Manufacturing and Trading of Pharmaceutical drugs | (9.02) | (10.55) | 21.48 | (19.57) | 15.30 | 2.72 |
| b) Consultancy Services | (233.60) | 14.89 | 580.87 | (218.71) | 755.84 | 255.66 |
| Total | (242.62) | 4.34 | 602.35 | (238.28) | 771.14 | 258.38 |
| Less: Interest | 0.00 | 0.52 | 11.36 | 0.52 | 22.94 | 47.66 |
| Total Profit before tax | (242.62) | 3.82 | 590.99 | (238.80) | 748.20 | 210.72 |
| Capital employed (Segment assets - segment liabilities) | | | | | | |
| Segment assets | | | | | | |
| a) Manufacturing and trading of Pharmaceutical drugs | 45.89 | 46.72 | 305.53 | 45.89 | 306.53 | 261.13 |
| b) Consultancy Services | 2,347.31 | 2,555.18 | 3,761.04 | 2,347.31 | 3,870.71 | 3,933.17 |
| Total Assets | 2,393.20 | 2,611.90 | 4,067.57 | 2,393.20 | 4,177.24 | 4,194.30 |
| Segment liabilities | | | | | | |
| a) Manufacturing and trading of Pharmaceutical drugs | 15.02 | 8.50 | 12.24 | 15.02 | 12.24 | 8.17 |
| b) Consultancy Services | 318.11 | 379.51 | 950.00 | 318.11 | 879.11 | 1,770.21 |
| Total Liabilities | 333.13 | 388.01 | 1,002.24 | 333.13 | 891.35 | 1,778.38 |

2. The above results for the quarter and half year ended 30 September 2023 were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 10.11.2023.

3. The financial results of the Group have been prepared in accordance with Ind AS prescribed under Section 133 of the Companies Act, 2013 ('the Act')

read with the relevant rules thereunder and in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015.

4. The above results as of 30.09.2023 include results of wholly owned subsidiary Decipher Software Solutions LLC, USA and step down subsidiary Decipher W.L.L., Bahrain.

5. The Group has consolidated financial results based on Ind AS 110 "Consolidated Financial Statements".

6. Comparative figures have been regrouped/reclassified to conform to the current period's/year's presentation.

For and on behalf of the Board



Sushant Mohan Lal
Director
DIN: 01227151



Place: Hyderabad
Date: 10.11.2023

Decipher Labs Limited
(CIN CL23230TG1986PLC006781)
Regd.off: 4th Floor, Plot No.94, Sagar Society,
Banjara Hills, Road No.2, Hyderabad, Telangana, India - 500034
URL: www.combatdrugs.in, email: info@combatdrugs.in, Ph: 040-48536100
Cash Flow Statement

All amounts in ₹ Lakhs, unless otherwise stated

| Particulars | Half Year Ended 30 September 2023 (Audited) | Year Ended 31 March 2023 (Audited) |
|-------------------------------------------------------------------------------------|---------------------------------------------------|------------------------------------------|
| Cash flow from operating activities | | |
| Profit before tax | -238.80 | -415.93 |
| Adjustments for : | | |
| Exchange differences on translating the financial statements of a foreign operation | 14.15 | 172.57 |
| Depreciation and amortisation expense | 22.43 | 42.75 |
| Finance costs | - | - |
| Loss on sale of asset | - | 7.34 |
| Balances written off | - | 228.57 |
| PPP loan written off | - | -722.20 |
| # | - | - |
| Operating Profit before Working Capital Changes | | |
| Changes in operating assets and liabilities | | |
| (Increase) / Decrease in Trade Receivables | 392.21 | 293.79 |
| (Increase) / Decrease in Inventories | 2.57 | - |
| (Increase) / Decrease in Other Assets | - | 555.71 |
| Increase / (Decrease) in Trade Payable | (22.08) | (110.89) |
| Increase / (Decrease) in Other Liabilities | (35.85) | (208.19) |
| Cash Generated from Operations | 134.63 | (156.48) |
| Income taxes paid | - | - |
| Net cash inflow (outflow) from operating activities | 134.63 | (156.48) |
| Cash flows from investing activities | | |
| Purchase of Fixed assets including Capital WIP | - | (78.30) |
| Investment in shares | 37.33 | (349.27) |
| Net cash inflow (outflow) from investing activities | 37.33 | (427.57) |
| Cash flow from financing activities | | |
| Proceeds/(repayment) of borrowings | (94.94) | (215.04) |
| Finance costs | - | - |
| Payment for lease liabilities | - | - |
| Net cash inflow (outflow) from financing activities | (94.94) | (215.04) |
| Net increase (Decrease) in cash and cash equivalents | 77.02 | (799.09) |
| Cash and Cash equivalents at the beginning of the Year | 741.77 | 1,540.86 |
| Less: Adjustment on account of cessation of Subsidiary company | - | - |
| Cash and Cash equivalents at the end of the Year | 818.78 | 741.77 |

For and on behalf of the Board



Sushant Mohan Lal
Director
DIN: 01227151



Place: Hyderabad
Date: 10.11.2023



Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Review Report to The Board of Directors
Decipher labs Limited (Formerly known as Combat Drugs Limited)

1. We have reviewed the accompanying statement of unaudited standalone financial results of Decipher labs Limited (Formerly known as Combat Drugs Limited) (the "Company") for the quarter ended 30th September, 2023 and year to date results for the period 1st April, 2023 to 30th September, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.S-2934)

K.Sreenivasan

Partner

Membership No.206421

UDIN: 23206421BGTHVI2679

Place : Secunderabad

Date : 10.11.2023





Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of
the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure
Requirements) Regulations, 2015

Review Report to The Board of Directors
Decipher labs Limited (Formerly known as Combat Drugs Limited)

1. We have reviewed the accompanying Statement of unaudited consolidated financial Results of Decipher labs Limited (Formerly known as Combat Drugs Limited) ("the Holding Company") and its subsidiaries, Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended 30th September, 2023 and year to date results for the period 1st April, 2023 to 30th September, 2023 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 March 29, 2019 issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable
4. The Statement includes the results of the subsidiary Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain.




Ramanatham & Rao

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the financial results of the subsidiaries referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial results of subsidiaries, Decipher Software Solutions LLC, USA and Decipher Soft Middle East W.L.L Bahrain included in the consolidated unaudited financial results whose interim financial results reflect total assets of of Rs. 2347.44 Lakhs as at 30th September, 2023, total revenues of Rs762.53lakhs and Rs. 1713.40 lakhs, total net profit after tax of Rs(186.80) lakhs and Rs. (269.39) lakhs, total comprehensive Income of Rs(186.31) lakhs and Rs. (269.39) lakhs for the quarter ended 30th September, 2023 and for the period from 1st April, 2023 to 30th September, 2023 respectively and net cash outflows of Rs81.74 Lakhs for the period from 1st April, 2023 to 30th September, 2023 as considered in the consolidated unaudited financial results. These Interim financial results have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the consolidated financial results, in so far as it relates to the amounts and disclosure included in respect of these subsidiaries is based solely on the report of such other auditor and the procedures performed by us are as stated in the paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

For Ramanatham & Rao
Chartered accountants
(Firm Registration No.S-2934)



K.Sreenivasan
Partner
Membership No.206421

UDIN: 23206421BGTHVJ5998
Place : Secunderabad
Date : 10.11.2023

